These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26648321)

  • 41. Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review.
    McGovern J; Dolan RD; Horgan PG; Laird BJ; McMillan DC
    J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1408-1417. PubMed ID: 34664431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse Effects of Low Preoperative Skeletal Muscle Mass in Patients Undergoing Gastrectomy for Gastric Cancer.
    Sakurai K; Kubo N; Tamura T; Toyokawa T; Amano R; Tanaka H; Muguruma K; Yashiro M; Maeda K; Hirakawa K; Ohira M
    Ann Surg Oncol; 2017 Sep; 24(9):2712-2719. PubMed ID: 28477088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events.
    Phuong A; Marquardt JP; O'Malley R; Holt SK; Laidlaw G; Eagle Z; Ngo S; Orcutt D; Schade GR; Lin DW; Schweizer MT; Yezefski T; Yu EY; Montgomery B; Grivas P; Fintelmann FJ; Psutka SP
    Urol Oncol; 2022 Oct; 40(10):456.e19-456.e30. PubMed ID: 36028450
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of weight-adjusted contrast enhancement on computed tomography-derived skeletal muscle measures: a retrospective proof-of-concept comparative study between Danish females and males.
    Brath MSG; Kristensen SV; Sahakyan M; Mark EB; Rasmussen HH; Østergaard LR; Frøkjær JB; Weinreich UM
    Am J Clin Nutr; 2024 Sep; 120(3):696-706. PubMed ID: 38936776
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Skeletal Muscle Depletion: A Risk Factor for Pneumonia following Gastric Endoscopic Submucosal Dissection in Elderly Patients.
    Arao M; Mizutani T; Ozawa N; Hanai T; Takada J; Kubota M; Imai K; Ibuka T; Shiraki M; Araki H; Ishihara T; Shimizu M
    Dig Dis; 2021; 39(5):435-443. PubMed ID: 33429392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
    Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
    Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CT-derived body composition and differential association with age, TNM stage and systemic inflammation in patients with colon cancer.
    Golder AM; Ferguson M; McMillan P; Mansouri D; Horgan PG; Roxburgh CS; Dolan RD; McGovern J; McMillan DC
    Sci Rep; 2024 Jul; 14(1):15673. PubMed ID: 38977870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients?
    Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):194-200. PubMed ID: 22524579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
    Bamias A; Karina M; Papakostas P; Kostopoulos I; Bobos M; Vourli G; Samantas E; Christodoulou Ch; Pentheroudakis G; Pectasides D; Dimopoulos MA; Fountzilas G
    Cancer Chemother Pharmacol; 2010 May; 65(6):1009-21. PubMed ID: 20130877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
    Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
    Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography.
    van Vugt JLA; Coebergh van den Braak RRJ; Schippers HJW; Veen KM; Levolger S; de Bruin RWF; Koek M; Niessen WJ; IJzermans JNM; Willemsen FEJA
    Clin Nutr; 2018 Oct; 37(5):1707-1714. PubMed ID: 28743427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
    Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Skeletal Muscle Mass Before Second-line Chemotherapy Correlates With Subsequent Prognosis and Rate of Late-line Chemotherapy in Patients With Unresectable Gastric Cancer.
    Matsunaga T; Satio H; Sakano YU; Makinoya M; Shimizu S; Shishido Y; Miyatani K; Kono Y; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
    Anticancer Res; 2023 Nov; 43(11):5051-5059. PubMed ID: 37909949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors associated with variability in skeletal muscle radiodensity in patients with metastatic cancer.
    Calixto-Lima L; Wiegert EVM; de Oliveira LC; Chaves GV; Avesani CM; Bezerra FF
    Nutrition; 2024 Apr; 120():112351. PubMed ID: 38330891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship between antitumor effects and relative dose intensity of S-1 plus cisplatin treatment for metastatic gastric cancer.
    Kitagawa M; Shimura T; Yamada T; Ebi M; Hirata Y; Mizoshita T; Tanida S; Kataoka H; Kamiya T; Joh T
    Anticancer Res; 2012 May; 32(5):1763-8. PubMed ID: 22593458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer.
    Xiao J; Caan BJ; Weltzien E; Cespedes Feliciano EM; Kroenke CH; Meyerhardt JA; Baracos VE; Kwan ML; Castillo AL; Prado CM
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):654-663. PubMed ID: 29675984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
    J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
    Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
    Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.